New Revision of the SCCS Notes of Guidance
The SCCS has issued a new revision of its notes of guidance for the testing of cosmetic ingredients and their safety evaluation. This 11th revision was adopted at its plenary meeting on 30-31 March this year, and it updates the 10th revision that was published in 2018.

The SCCS Notes of Guidance for the Testing of Cosmetic Ingredients and Their Safety Evaluation

The European Commission’s Scientific Committee on Consumer Safety (SCCS) provides opinions on health and safety risks (chemical, biological, mechanical and other physical risks) of non-food consumer products (e.g., cosmetic products and their ingredients) and services. The members of the SCCS also compile an important document called “The SCCS Notes of Guidance for the Testing of Cosmetic Ingredients and Their Safety Evaluation” which is particularly important for assessing cosmetic and personal care products’ safety in the European Union (EU).

These Notes of Guidance (NOGs) contain relevant information about the testing requirements and safety evaluation of cosmetic substances in the Europe Union (EU). Its main purpose is to guide the cosmetic industry and public authorities in order to improve harmonized compliance with the current cosmetic EU legislation (Cosmetics Regulation (EC) No. 1223/2009) and “provide assistance in the complex process of the testing and safety evaluation of cosmetic ingredients in the EU”.

Following the progress of scientific knowledge in general and the experience gained (especially in the field of cosmetics), NOGs are regularly revised and updated. The last revision (10th – SCCS/1602/18) was adopted in 2018. Last month (March 2021) it has been updated by the 11th revision (SCCS/1628/21).

According to the European Cosmetics Regulation, in vivo testing of finished products (11th March 2004), in vivo testing for local toxicity (11th March 2009) and in vivo testing for repeated dose toxicity (including sensitization), toxicokinetics and developmental toxicity of ingredients (11th March 2013) for the purpose of cosmetics is prohibited.  In recent years, there were important developments and validation of alternative methods, therefore the 11th revision of the NOGs focus on exposure and the application of alternative methods, specifically on non-animal methods/new approach methodology (NAM).

References:

  1. Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products – https://ec.europa.eu/health/sites/health/files/endocrine_disruptors/docs/cosmetic_1223_2009_regulation_en.pdf
  2. Scientific Committee on Consumer Safety (SCCS) – The SCCs Notes of Guidance for the Testing of Cosmetic Ingredients and their Safety Evaluation. 11th Revision. SCCS/1628/21 – https://ec.europa.eu/health/sites/health/files/scientific_committees/consumer_safety/docs/sccs_o_250.pdf
  3. Scientific Committee on Consumer Safety (SCCS) – The SCCs Notes of Guidance for the Testing of Cosmetic Ingredients and their Safety Evaluation. 10th Revision. SCCS/1602/18 – https://ec.europa.eu/health/sites/health/files/scientific_committees/consumer_safety/docs/sccs_o_224.pdf

further
reading

medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
parfum_fragrance_allergen_1
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »